Clinical trials: NK Cell
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of…
- Conditions
- Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma
- Trial name
- NCT03598998
- Testing
- Pembrolizumab, Pralatrexate
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
T-cell Lymphoma, NK-Cell Lymphoma
A Registry for People With T-cell Lymphoma
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma.
- Conditions
- T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia
- Trial name
- NCT05978141
- Testing
- Optional Blood Sample and Nail Sample
- Where
- 26 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response…
- Conditions
- HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma
- Trial name
- NCT02797470
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- AIDS Malignancy Consortium
Peripheral T-cell Lymphoma, NK/T-Cell Lymphoma
Circulating Tumor DNA in Peripheral T-cell Lymphomas
The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance…
- Trial name
- CIRCULATE (NCT06362148)
- Testing
- Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay, 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Extranodal NK/T-cell Lymphoma
Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma
Extranodal NK/T-cell lymphoma (ENKTCL) is an Epstein-Barr virus-associated non-Hodgkin lymphoma with high incidence in Asia and Latin America.
- Trial name
- NCT07554482
- Testing
- Pegaspargase (PEG) Asparaginase, Gemcitabine (GEM), Oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Beijing Tongren Hospital
Complete Remission Rate， CRR, Progression Free Survival
Sintilimab, Chidamide, and Azacitidine for Untreated Stage I-II Extranodal NK/T-Cell Lymphoma
This is an open-label, single-arm, multi-center Phase II clinical trial evaluating the efficacy and safety of a novel sequential regimen as first-line therapy for treatment-naïve patients with Extranodal NK/T-cell Lymphoma…
- Conditions
- Complete Remission Rate， CRR, Progression Free Survival, Overall Survival, Adverse Event
- Trial name
- SCENT-3 (NCT07542912)
- Testing
- SCA Induction followed by Response-Adapted Therapy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
This phase II trial studies how well reduced intensity donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01384513
- Testing
- Fludarabine, Busulfan, Total Body Irradiation (TBI)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)
Extranodal NK/T-cell lymphoma (NKTCL) is an aggressive EBV-associated lymphoma with poor prognosis, highly prevalent in China. Early-stage NKTCL achieves favorable long-term survival, while advanced disease shows dismal outcomes…
- Trial name
- NCT07525466
- Testing
- Mitoxantrone liposome, Etoposide, Pegaspargase (PEG) Asparaginase
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Tongren Hospital
T-Cell and NK-Cell Neoplasm
A Global Study of the PETAL Consortium
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or…
- Trial name
- PETAL (NCT06067347)
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Lymphoma, Extranodal NK-T-Cell
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma
Aim of the trial is to evaluate the activity and tolerability of the anti PD1 agent Pembrolizumab in combination with RadioTherapy for the initial treatment of previously untreated patients with limited stage NK/T cell lymphoma…
- Trial name
- NCT04417166
- Testing
- Pembrolizumab, Involved Field Radiation Therapy
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis
Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis
This study investigates the impact of letermovir prophylaxis on viral infections (including CMV, EBV, BKV, HHV-6/7, RSV, ADV, HSV, etc.) following allogeneic hematopoietic stem cell transplantation in pediatric patients with…
- Conditions
- EBV-associated T/NK-cell Lymphoproliferative Diseases, Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis, Letermovir
- Trial name
- NCT07488728
- Testing
- Letermovir
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Beijing Children's Hospital
NK T-Cell Lymphoma
Phaes Ⅱ Study of Golidocitinib-Pegaspargase-PD-1 Antibody First-Line for Advanced ENKTL
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive non-Hodgkin lymphoma with poor prognosis in advanced stages, with a 5-year overall survival (OS) rate of less than 30% despite asparaginase-based regimens.
- Trial name
- NCT07457177
- Testing
- Golidocitinib + Pegaspargase + Anti-PD-1 mAb
- Volunteers
- 40 people
- Sponsor
- LIANG WANG
NK/T Cell Lymphoma Nos
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type
The purpose of this multi-center,single arm,phase Ⅱ clinical trail is to determine the safety and efficacy of Sintilimab with P-GemOx (pegaspargase, gemcitabine and oxaliplatin) regimen for newly diagnosed advanced extranodal…
- Trial name
- NCT04127227
- Testing
- sintilimab,pegaspargase,gemcitabine,oxaliplatin
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Sun Yat-sen University
Extranodal NK/T-cell Lymphoma
Golidocitinib Combined With P-GemOx Plus PD-1 Inhibitor Versus P-GemOx Plus PD-1 Inhibitor in First-Line Newly Diagnosed Advanced or Non-Nasal Extranodal NK/T-Cell Lymphoma
This is a multicenter, randomized, Phase 2 clinical trial designed to evaluate the efficacy and safety of golidocitinib combined with the P-GemOx (pegaspargase + gemcitabine + oxaliplatin) regimen plus PD-1 inhibitor, compared…
- Trial name
- NCT07385989
- Testing
- Golidocitinib in combination with P-GEMOX and PD-1 inhibitor, PD-1 inhibitor in combination with P-GEMOX
- Volunteers
- 40 people
- Sponsor
- WEI XU
NK-T-Cell Lymphoma, Extranodal
PET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
A prospective, open-abel, phase 2 clinical study to investigate whether interim Positron Emission Tomography (PET) and Epstein-Barr virus (EBV) DNA-directed therapy can improve the prognosis of localized nasal extranodal NK/T…
- Trial name
- ENKTL (NCT06069830)
- Testing
- 4 cycles of ESA regimen with sandwiched radiotherapy, 2 cycles of ESA regimen sequential radiotherapy and 2 cycles of PD-1 monoclonal antibody combined with pegaspargase, 2 cycles of ESA regimen, 2 cycles of PD-1 monoclonal antibody and concurrent radiotherapy, 2 cycles of PD-1 monoclonal antibody combined with pegaspargase
- Where
- China
- Volunteers
- 89 people
- Sponsor
- Ruijin Hospital
Mature T-cell and NK-cell Lymphoma
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas
This is a prospective, multicenter, open-label, phase Ib/II clinical study to evaluate the safety and efficacy of EZH2 inhibitor Zeprumetostat in combination therapy for patients with relapsed or refractory mature T-cell and…
- Trial name
- NCT07339527
- Testing
- Zeprumetostat, Golidocitinib, Chidamide
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This phase II trial studies how well pembrolizumab and external beam radiation therapy work in treating patients with non-Hodgkin lymphoma that has come back (relapsed) or does not respond to treatment (refractory).
- Conditions
- Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
- Trial name
- NCT03210662
- Testing
- External Beam Radiation Therapy, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after…
- Trial name
- TOUCH (NCT04425070)
- Testing
- ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
- Where
- 13 sites in China
- Volunteers
- 56 people
- Sponsor
- Antengene Corporation
NK T-Cell Lymphoma
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
Allogeneic hematopoietic stem cell transplantation is an important treatment method for NK-T cell lymphoma, but the recurrence rate after transplantation is relatively high.
- Trial name
- NCT07276698
- Testing
- Selinexor, azacitidine
- Volunteers
- 39 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
NK T-Cell Lymphoma
Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma
Evaluation of the efficacy and safety of Thiotepa combined with Cyclophosphamide and Busulfan as conditioning regimen before allo-HSCT for the treatment of NK/T cell lymphoma
- Trial name
- NCT07276737
- Testing
- Thiotepa
- Volunteers
- 37 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine